Attention-Deficit/Hyperactivity Disorder References

Last updated: 11 November 2024
  1. Ghuman JK, Arnold LE, Anthony BJ. Psychopharmacological and other treatments in preschool children with attention-deficit/hyperactivity disorder: current evidence and practice. J Child Adolesc Psychopharmacol. 2008 Oct;18(5):413-447. doi: 10.1089/cap.2008.022. PMID: 18844482
  2. Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007 Jul;46(7):894-921. PMID: 17581453
  3. Millichap JG. Etiologic classification of attention-deficit/hyperactivity disorder. Pediatrics. 2008 Feb;121(2):e358-e365. doi: 10.1542/peds.2007-1332. PMID: 18245408
  4. Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011 Nov;128(5):1007-1022. doi: 10.1542/peds.2011-2654. Accessed 22 Jan 2012. PMID: 22003063
  5. Smoot LC, Boothby LA, Gillett RC. Clinical assessment and treatment of ADHD in children. Int J Clin Pract. 2007 Oct;61(10):1730-1738. PMID: 17877659
  6. National Collaborating Centre for Mental Health. Diagnosis and management of ADHD in children, young people and adults. Attention Deficit Hyperactivity Disorder. London: The British Psychological Society, The Royal College of Psychiatrists; 2006
  7. MedWormhttp://www.medworm.com/rss/index.php/Pediatrics/33/http://www.medworm.com/rss/medicalfeeds/specialities/Pediatrics.xml
  8. MedWorm http://www.medworm.com/rss/index.php/Psychiatry/172/ www.medworm.com/rss/medicalfeeds/specialities/Psychiatry-News.xml
  9. Krull KR. Attention deficit hyperactivity disorder in children and adolescents: pharmacotherapy. UpToDate. https://www.uptodate.com. 06 Jan 2012. Accessed 22 Jan 2012.
  10. Krull KR. Attention deficit hyperactivity disorder in children and adolescents: clinical features and evaluation. UpToDate. https://www.uptodate.com. 06 Jan 2012. Accessed 22 Jan 2012.
  11. National Collaborating Centre for Mental Health. Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults. CG 72. National Institute for Health and Clinical Excellence. http://guidance.nice.org.uk. Sep 2008.
  12. University of Michigan Health System. Attention-deficit hyperactivity disorder. University of Michigan. http://ocpd.med.umich.edu. Oct 2005.
  13. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). CADDRA: Canadian ADHD practice guidelines. 3rd Ed. CADDRA. http://www.caddra.ca/. 2011.
  14. Dobie C, Donald WB, Hanson M, et al; Institute for Clinical Systems Improvement (ICSI). Diagnosis and management of attention deficit hyperactivity disorder in primary care for school-age children and adolescents. ICSI. https://www.icsi.org/. Mar 2012.
  15. Cincinnati Children’s Hospital Medical Center. Evidence-based clinical practice guideline for outpatient evaluation and management of attention deficit/hyperactivity disorder. http://www.cincinnatichildrens.org. Apr 2004
  16. Institute for Clinical Systems Improvement (ICSI). Health care guideline: diagnosis and management of attention-deficit hyperactivity disorder in primary care for school age children and adolescents. ICSI. http://www.icsi.org. Jan 2005.
  17. Scottish Intercollegiate Guidelines Network (SIGN). Management of attention deficit and hyperkinetic disorders in children and young people. SIGN. http://www.sign.ac.uk. 2009.
  18. National Institute for Health and Care Excellence (NICE). Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. NICE. http://www.nice.org.uk. Mar 2006.
  19. American Psychiatric Association. Attention-Deficit/Hyperactivity Disorder. In: Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013:59-61.
  20. Ministry of Health Singapore (MOH). Clinical practice guidelines attention deficit hyperactivity disorder. MOH Singapore. http://www.moh.gov.sg. 2014 Jan. Accessed 22 Sep 2015.
  21. National Institute for Health and Care Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management. NICE. https://www.nice.org.uk. 14 Mar 2018. Accessed 23 Jul 2018.
  22. French WP. Assessment and treatment of attention-deficit/hyperactivity disorder: part 1. Pediatr Ann. 2015 Mar;44(3):114-120. doi: 10.3928/00904481-20150313-13. PMID: 25806728
  23. Wolraich ML, Hagan JF Jr, Allan C, et al. Subcommittee on Children and Adolescents with Attention-Deficit/Hyperactive Disorder. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019 Oct;144(4):e20192528. doi: 10.1542/peds.2019-2528. Accessed 26 Feb 2021. PMID: 31570648
  24. Substance Abuse and Mental Health Services Administration. Impact of the DSM-IV to DSM-5 Changes on the National Survey on Drug Use and Health [Internet]. Rockville (MD): Substance Abuse and Mental Health Services Administration (US). 2016 Jun. Accessed 13 Nov 2020. PMID: 30199183
  25. Krull KR. Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents. UpToDate. https://www.uptodate.com. 24 Feb 2020. Accessed 01 Mar 2021.
  26. Krull KR. Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications. UpToDate. https://www.uptodate.com. 10 Mar 2020. Accessed 01 Mar 2021.
  27. Krull KR. Attention deficit hyperactivity disorder in children and adolescents: overview of treatment and prognosis. UpToDate. https://www.uptodate.com. 10 Oct 2019. Accessed 01 Mar 2021.
  28. Krull KR. Attention deficit hyperactivity disorder in children and adolescents: clinical features and diagnosis. UpToDate. https://www.uptodate.com. 27 Nov 2019. Accessed 01 Mar 2021.
  29. Almagor D, Duncan D, Gignac M, et al. CADDRA - Canadian ADHD Resource Alliance: Canadian ADHD practice guidelines, 4.1 Edition, Toronto ON. CADDRA. https://www.caddra.ca. Jan 2020. Accessed 04 Mar 2021.
  30. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Text Revision. 5th ed. Washington, DC: American Psychiatric Association; 2022.
  31. Manor I, Magen A, Keidar D, et al. The effect of phosphatidylserine containing omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension. Eur Psychiatry. 2012 Jul;27(5):335-342. doi: 10.1016/j.eurpsy.2011.05.004. PMID: 21807480
  32. Bukstein, O. Attention deficit hyperactivity disorder in adults: Epidemiology, clinical features, assessment, and diagnosis. UpToDate. https://www.uptodate.com. Apr 07 2022.
  33. Nguyen S, Nguyen C, Chudnow R, et al. Efficacy of EPA enriched phosphatidylserine-omega-3 (Vayarin) on children with ADHD (P7.336). Neurology. 2014 Apr;82(Suppl 10). https://n.neurology.org/.
  34. Gomez R, Chen W, Houghton S. Differences between DSM-5-TR and ICD-11 revisions of attention deficit/hyperactivity disorder: a commentary on implications and opportunities. World J Psychiatry. 2023 May;13(5):138-143. doi: 10.5498/wjp.v13.i5.138. Accessed 01 Jul 2024. PMID: 37303925
  35. Brent AD.Bukstein OG, Solanto MV. Attention deficit hyperactivity disorder in adults: treatment overview. UpToDate. https://www.uptodate.com.. 19 Jul 2023.
  36. Olagunju AE, Ghoddusi F. Attention-deficit/hyperactivity disorder in adults. Am Fam Physician. 2024 Aug;110(2):157-166. PMID: 39172673